Related Experiment Videos
Surgery of primary retroperitoneal tumours
1Department of Surgery, National Institute of Oncology, Budapest, Hungary.
Summary
This study on primary retroperitoneal tumors found that while imaging like MRI improved diagnostics, surgical outcomes for high-grade malignant tumors remain poor. Complete removal is advised for benign and low-grade malignant cases.
Area of Science:
- Oncology
- Surgical Pathology
- Diagnostic Imaging
Background:
- Primary retroperitoneal tumors (PRTs) are rare and can be challenging to diagnose and treat.
- Advances in imaging modalities have improved diagnostic capabilities for PRTs.
- The therapeutic outcomes for PRTs, especially malignant types, have historically been limited.
Purpose of the Study:
- To analyze the diagnostics and complex therapy of primary retroperitoneal tumors.
- To evaluate the effectiveness of surgical interventions for benign and malignant PRTs.
- To assess the role of advanced imaging and adjuvant therapies in managing PRTs.
Main Methods:
- Retrospective analysis of 112 cases of retroperitoneal space-reducing processes.
- Surgical operations performed on 62 adult patients with primary retroperitoneal tumors (12 benign, 50 malignant).
- Review of diagnostic data from computed radiography (CR), magnetic resonance imaging (MRI), and ultrasonography (USG).
Main Results:
- Despite advancements in CR, MRI, and USG, therapeutic results for PRTs have not significantly improved.
- Total tumor extirpation is recommended for benign lesions, even with extensive multivisceral resections.
- For high-grade malignant PRTs, ultraradical surgical interventions did not yield promising results and are not recommended.
- Radio- and chemotherapy show only promising, rather than notable, achievements in the complex management of PRTs.
Conclusions:
- Surgical management of benign and low-grade malignant PRTs should focus on complete tumor extirpation.
- Aggressive surgical approaches for high-grade malignant PRTs are not supported by current evidence.
- Further research is needed to improve the efficacy of adjuvant therapies like radio- and chemotherapy for PRTs.